Reported 2 days ago
Medtronic announced plans to separate its diabetes business into an independent entity due to recent struggles and regulatory issues, despite returning to growth with six consecutive quarters of double-digit growth. The new company will be led by Que Dallara, head of the diabetes unit, and aims for immediate profitability through tailored commercial strategies. The separation is expected within 18 months, following an initial public offering. Medtronic also forecasted lower-than-expected earnings for 2026, impacted by potential tariff challenges.
Source: YAHOO